<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Buschke-Ollendorff syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Buschke-Ollendorff syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Buschke-Ollendorff syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine C McCuaig, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Miedzybrodzki, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2793311278"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Buschke-Ollendorff syndrome (BOS; MIM #166700) is a rare, inherited, autosomal dominant disorder with high penetrance and variable expressivity characterized by the presence of sclerotic bone lesions in association with connective tissue nevi (CTN; elastomas and collagenomas) [<a href="#rid1">1,2</a>]. BOS results from heterozygous, loss-of-function mutations in the <em>LEMD3</em> gene on the chromosome band 12q14 [<a href="#rid1">1,3</a>]. Most patients present with both CTN and bone lesions, but some have only skin or skeletal lesions.</p><p class="headingAnchor" id="H1665661375"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>First described in 1928 by Buschke and Ollendorff as dermatofibrosis lenticularis disseminata, the disease has been reported under a variety of names, including dermatofibrosis lenticularis disseminata with osteopoikilosis, dermatofibrosis disseminated with osteopoikilosis (spotted bones), dermato-osteopoikilosis, dermato-osteopoikilosis with melorheostosis (a dripping wax appearance along the outer bone), osteopathia condensans disseminata, and connective tissue nevus syndrome.</p><p class="headingAnchor" id="H1950809892"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>BOS is a rare condition, with an estimated incidence of 1 in 20,000 individuals [<a href="#rid4">4</a>]. The precise incidence and prevalence are unknown, as both the cutaneous lesions and bone lesions are usually asymptomatic and detected incidentally [<a href="#rid2">2,5,6</a>]. Males and females are equally affected. Both inherited and sporadic forms have been described [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3945094364"><span class="h1">GENETICS AND PATHOGENESIS</span><span class="headingEndMark"> — </span>BOS is an autosomal dominant disorder with high penetrance and variable expressivity caused by loss-of-function germline variants in the LEM domain-containing protein 3<em> </em>(<em>LEMD3</em>) gene (also called <em>MAN1</em>) on chromosome 12q14 [<a href="#rid8">8</a>]. More than 125 pathogenic variants of the <em>LEMD3</em> gene have been detected, the vast majority of which are point mutations [<a href="#rid3">3,9-19</a>].</p><p>There are two reports that highlight that a localized loss of the ribonucleic acid (RNA) recognition motif (RRM) of the <em>LEMD3 </em>gene, and not necessarily the loss of the entire LEMD3 protein, can also cause the characteristic findings of BOS [<a href="#rid10">10,11</a>]. In addition, even patients who possess the same genetic defect will show differences in skin and bone expression. There are two reports of BOS occurring in families without an <em>LEMD3</em> pathogenic variant [<a href="#rid7">7,12</a>], suggesting that there may be other potential genes involved in the pathogenesis of BOS and connective tissue nevi (CTN).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Connective tissue nevi</strong> – <em>LEMD3</em> encodes an inner nuclear membrane protein that antagonizes the bone morphogenic proteins (BMPs) and transforming growth factor (TGF)-beta signaling pathways through interactions with specific SMAD transcriptor family proteins. The structural basis for some of these specific interactions has been evaluated [<a href="#rid20">20</a>]. Loss-of-function mutations in <em>LEMD3</em> result in upregulation of the downstream targets in both of these pathways, leading to alteration of fibroblast function and increased bone formation. Fibroblasts in affected patients produce more tropoelastin and elastin via enhanced TGF-beta and BMP signaling, resulting in the characteristic cutaneous phenotype [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteopoikilosis</strong> – Osteopoikilosis (OPK) is characterized by a symmetric, but variable, distribution of multiple areas of hyperostosis in different parts of the skeleton [<a href="#rid8">8</a>]. These areas represent foci of dense lamellar bone within spongy bones. The exact pathogenesis of OPK is unknown; it is thought to be a multifactorial process that may involve [<a href="#rid23">23</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An inherited, abnormal formation of trabeculae along lines of stress</p><p class="bulletIndent2"><span class="glyph">•</span>A focal defect of endochondral ossification</p><p class="bulletIndent2"><span class="glyph">•</span>Altered osteogenesis</p><p class="bulletIndent2"><span class="glyph">•</span>Specific <em>LEMD3</em> mutations</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melorheostosis</strong> – Melorheostosis is a rare, sclerosing hyperostosis usually affecting the appendicular skeleton in a limited and unilateral segment. It is an isolated disorder in most cases but can rarely occur in patients with BOS with or without CTN [<a href="#rid24">24,25</a>]. This mixed sclerosing bone dysplasia is characterized by abnormalities of endochondral and membranous ossification, with ectopic bone forming on the periosteal and endosteal surfaces of the long bones [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1">While germline <em>LEMD3</em> variants have been identified in patients with BOS who present with OPK and melorheostosis [<a href="#rid28">28</a>], no germline or somatic <em>LEMD3</em> variants have been identified in cases of isolated melorheostosis. The majority of cases of isolated melorheostosis are caused by somatic <em>MAP2K1</em> variants, while a minority of cases are associated with somatic variants in other genes in related pathways (eg, <em>KRAS</em>) [<a href="#rid24">24,29</a>].</p><p></p><p class="headingAnchor" id="H3055490799"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H14893924"><span class="h2">Skin lesions</span><span class="headingEndMark"> — </span>Connective tissue nevi (CTN) are hamartomas that arise in the reticular dermis. Since routine hematoxylin and eosin stains cannot differentiate collagen and elastic fiber, special stains are required for the accurate histopathologic diagnosis of CTN. These include hematoxylin phloxine saffron stain, which stains collagen in yellow and elastic fibers in red; Masson's trichrome stain; orcein; Weigert; and Verhoeff-van Gieson [<a href="#rid10">10,30-35</a>].</p><p>CTN are characterized by the abnormal accumulation of components of the extracellular dermal matrix, specifically collagen, elastin, and proteoglycans [<a href="#rid30">30</a>]. They typically show a normal or papillomatous epidermis overlying an unaffected papillary dermis. Based upon the predominance of collagen or elastic fibers in the reticular dermis, CTN have been divided into three histopathologic groups [<a href="#rid18">18,36,37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pure collagenoma</p><p class="bulletIndent1"><span class="glyph">●</span>Pure elastoma</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed CTN</p><p></p><p>However, the histopathologic findings can be very heterogeneous, with most lesions showing both collagen and elastin fiber abnormalities.</p><p>Pure collagenoma demonstrates accumulation of dense and coarse collagen fibers in the reticular dermis with either an irregular or regular distribution, sometimes associated with a relative reduction in the number of elastic fibers  (<a class="graphic graphic_picture graphicRef109065" href="/z/d/graphic/109065.html" rel="external">picture 1</a>) [<a href="#rid36">36</a>]. Pure elastomas show broad, ramified, interlaced, and sometimes clumped elastic fibers in the reticular dermis, whereas mixed-type CTN show both collagen and elastic fiber abnormalities without a specific pattern  (<a class="graphic graphic_picture graphicRef109067" href="/z/d/graphic/109067.html" rel="external">picture 2</a>) [<a href="#rid31">31</a>]. Mucin deposition may be present in elastomas [<a href="#rid18">18,37</a>].</p><p>Elastomas are the most common type of CTN found in patients with BOS. Collagenomas or CTN with mixed features of elastoma and collagenoma have been reported in approximately one-third of patients [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2002614655"><span class="h2">Bone lesions</span><span class="headingEndMark"> — </span>Bone lesions of osteopoikilosis (OPK) are not routinely biopsied unless there is doubt about the underlying diagnosis. On histopathologic assessment, sclerotic bone samples demonstrate foci of thickened trabeculae of lamellar bone. These foci vary in thickness but are arranged in a regular pattern, similar to that of normal spongiosus bone. This histology is similar to that of bone islands. Osteoclasts and osteoblasts are present in the sections, although they do not show increased activity [<a href="#rid38">38</a>].</p><p>Histopathologic features of melorheostosis include variable degrees of cortical bone thickening and fibrotic changes within the bone marrow space. The bone structure is irregular, with mixed areas of lamellar and woven bone. The associated soft tissue masses are composed of a mixture of osteocartilaginous, fibrovascular, and adipose tissue [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H3443014994"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>BOS is characterized by the association of multiple connective tissue nevi (CTN) with osteopoikilosis (OPK; "spotted bones"). In a review of 164 published cases of BOS, 6 percent of the patients had neurologic deficits, and 5 percent had cognitive delays [<a href="#rid2">2</a>]. (See <a class="local">'Associated conditions'</a> below.)</p><p class="headingAnchor" id="H3054100056"><span class="h2">Connective tissue nevi</span><span class="headingEndMark"> — </span>Connective tissue nevi (CTN) are hamartomas that arise in the reticular dermis. They include elastomas (most common), collagenomas, and mixed lesions (see <a class="local">'Skin lesions'</a> above). CTN present as painless, scattered, flesh-colored or yellowish papules or nodules 2 to 10 mm in size (dermatofibrosis lenticularis disseminata) or as more localized, grouped nodules or plaques 3 to 10 cm in size that may only be appreciated by palpation  (<a class="graphic graphic_picture graphicRef117912 graphicRef107838 graphicRef109069" href="/z/d/graphic/117912.html" rel="external">picture 3A-C</a>) [<a href="#rid18">18</a>].</p><p>CTN may be congenital and/or acquired, progressing with time to adolescence. The disseminated lesions are symmetrically distributed, primarily on the trunk and volar surfaces of the proximal extremities. Rarely, the neck, scalp, face, and hands can be involved  (<a class="graphic graphic_picture graphicRef109070" href="/z/d/graphic/109070.html" rel="external">picture 4</a>). Localized plaques are usually located on the trunk and limbs in a segmental or linear pattern.</p><p>The so-called "juvenile elastomas" are almost exclusively found in BOS. Juvenile elastomas with OPK lacking the germline <em>LEMD3</em> mutation are diagnosed as BOS all the same [<a href="#rid7">7,12</a>]. Isolated juvenile elastomas, in the absence of OPK, are thought to be an incomplete manifestation of BOS [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H3285069024"><span class="h2">Skeletal lesions</span></p><p class="headingAnchor" id="H1142459697"><span class="h3">Osteopoikilosis</span><span class="headingEndMark"> — </span>Osteopoikilosis (OPK; also called osteopathia condensans disseminata, spotted bones, osteosclerosis disseminata, osteosclerosis familiaris disseminata, and osteosclerosis fragilis generalisata) is a sclerosing bone dysplasia consisting of focal deposits of dense lamellar bone in the spongiosa [<a href="#rid26">26</a>]. In BOS, OPK displays incomplete penetrance and variable phenotypic expression and, therefore, may not be detected in all patients or may be the sole manifestation of the disease [<a href="#rid2">2</a>].</p><p>OPK typically affects the small tubular bones of the hands and feet, meta-epiphyseal regions of the long bones, and the pelvic bones. The hands are involved in nearly all patients, followed by the feet, pelvis, and long bones [<a href="#rid39">39</a>]. The ribs, skull, and vertebrae are typically spared. Lesions are symmetric but randomly distributed [<a href="#rid40">40</a>].</p><p>OPK is usually asymptomatic and is typically an incidental finding on imaging studies for unrelated conditions. Some patients may report articular pain or, rarely, joint effusions [<a href="#rid2">2,5,41,42</a>]. However, whether these symptoms are truly related to the underlying osteopoikilotic lesions remains to be established.</p><p>Although OPK can present at any age, it is detected by late childhood or puberty in most cases. Lesions usually persist throughout life.</p><p class="headingAnchor" id="H1085809418"><span class="h4">Radiologic findings</span><span class="headingEndMark"> — </span>On plain radiographs, osteopoikilotic lesions appear as round, oval, or linear, hyperdense opacities, ranging in size from 2 to 10 mm  (<a class="graphic graphic_picture graphicRef109072" href="/z/d/graphic/109072.html" rel="external">picture 5</a>). The number of lesions in a single bone ranges from a few to hundreds and tends to increase with age. The largest number of lesions is usually detected in the pelvic bones [<a href="#rid39">39</a>]. In children, lesions may increase or decrease in size over time and, in rare instances, may even disappear completely [<a href="#rid5">5</a>]. In adults, osteopoikilotic lesions are usually stable and persist throughout life [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3162946715"><span class="h3">Melorheostosis</span><span class="headingEndMark"> — </span>Melorheostosis is an exceedingly rare, sclerosing bone dysplasia characterized by a "flowing" hyperostosis of the cortex of tubular bones with a radiologic appearance of "dripping candle wax" [<a href="#rid24">24,26,44-46</a>]. It can occur as an isolated disorder or as a very uncommon manifestation of BOS, alone or in association with OPK (mixed or overlap sclerosing bone dysplasia) [<a href="#rid25">25,28,38</a>].</p><p>Melorheostosis may affect a single bone (monostotic form) or multiple adjacent bones (polyostotic form) and typically has a unilateral or segmental distribution. Based on data from large case series, the appendicular skeleton and, in particular, the lower extremities appear to be most frequently involved [<a href="#rid45">45,47</a>].</p><p>In most cases, melorheostosis lesions are asymptomatic and found incidentally on imaging studies for unrelated conditions. The most reported symptom is local pain at the site of melorheostosis [<a href="#rid24">24,45,48</a>]. However, in some patients, melorheostosis may be associated with limb deformity, leg length discrepancy, reduced range of motion, paresthesia, and/or weakness [<a href="#rid24">24,26,28,45,49-51</a>].</p><p>Abnormalities of overlying soft tissues have been reported in some patients. These include myositis ossificans; contractures; linear scleroderma-like skin lesions; and patchy, erythematous, vascular lesions [<a href="#rid13">13,48,52-54</a>]. Histologically, these vascular lesions show thickened vascular wall and increased density of superficial vessels compared with skin from the contralateral extremity [<a href="#rid53">53</a>]. Hypertrichosis, hyperpigmentation, ipsilateral epidermal nevus, and sebaceous nevus have also been reported at the site of melorheostosis [<a href="#rid52">52,55</a>].</p><p class="headingAnchor" id="H843986989"><span class="h2">Syndromic Buschke-Ollendorff syndrome</span><span class="headingEndMark"> — </span>Characteristic syndromic manifestations that are associated with the 12q14 microdeletion syndrome that encompasses <em>LEMD3</em> include short stature and developmental delay, which have been reported in association with BOS [<a href="#rid56">56</a>]. A syndromic variant, characterized by late-onset generalized morphea, lichen sclerosus and atrophicus, and OPK, has been reported in a patient with an identified new mutation in <em>LEMD3</em> [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H907730805"><span class="h2">Associated conditions</span><span class="headingEndMark"> — </span>Although there is no definite link between BOS and other diseases, multiple associations have been described in the literature, most often in single case reports. They include ossifying fibroma [<a href="#rid57">57</a>], bilateral cutaneous syndactyly [<a href="#rid58">58</a>], otosclerosis and congenital spine stenosis [<a href="#rid59">59</a>], hypertrophic scarring [<a href="#rid60">60</a>], and PASH (pyoderma gangrenosum, acne, and suppurative hidradenitis) syndrome [<a href="#rid61">61</a>]. However, it is unclear if these are true associations or coincidental findings [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H2648394026"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of BOS is based upon the finding of multiple cutaneous lesions with histopathologic features of connective tissue nevi (CTN) associated with osteopoikilosis (OPK) detected on plain radiographs. </p><p class="headingAnchor" id="H3568904474"><span class="h2">When to suspect Buschke-Ollendorff syndrome</span><span class="headingEndMark"> — </span>The diagnosis of BOS is suspected in a patient presenting with multiple cutaneous lesions with clinical and histopathologic features of CTN or in a patient with osteopoikilotic lesions found incidentally on radiologic studies for unrelated conditions. (See <a class="local">'Radiologic findings'</a> above.)</p><p class="headingAnchor" id="H2603517028"><span class="h2">Diagnostic workup</span><span class="headingEndMark"> — </span>The diagnostic workup of a patient with suspected BOS may involve a careful personal and family history, physical examination, skin biopsy, radiologic studies, and genetic testing.</p><p class="headingAnchor" id="H1382444252"><span class="h3">History and physical examination</span><span class="headingEndMark"> — </span>Patients should be questioned for any personal or family history of skin lesions suggestive of CTN as well as of any bone lesions found on radiologic investigations suggestive of OPK. In a review of 164 published cases of BOS, a positive family history was noted in 92 percent of patients [<a href="#rid2">2</a>].</p><p>Any prior imaging studies from the patient and from any suspected affected family members should also be reviewed. Because of the highly variable expressivity of the disease, the extent of specific skin and skeletal findings is unpredictable within any affected family.</p><p>Total body skin examination should be performed to identify CTN or other skin lesions. Although CTN are the initial manifestation of BOS in most cases, they may go unnoticed if they are small and in limited number. Musculoskeletal examination is often noncontributory since OPK is usually asymptomatic. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H3439933085"><span class="h3">Skin biopsy</span><span class="headingEndMark"> — </span>A full-thickness punch biopsy of a cutaneous lesion that also includes perilesional normal skin for comparison will provide an optimal specimen for histopathologic assessment [<a href="#rid30">30</a>]. In addition to routine histologic stains, specific elastic and collagen fiber staining is required to determine the CTN type. (See <a class="local">'Pathology'</a> above.)</p><p>Skeletal lesions are not normally biopsied, as the diagnosis of OPK can usually be confirmed by means of radiographic imaging.</p><p class="headingAnchor" id="H268975392"><span class="h3">Radiologic imaging</span><span class="headingEndMark"> — </span>Patients who present with multiple CTN should undergo radiologic investigation with plain radiographs to detect OPK lesions. These lesions typically appear as multiple rounded, dense opacities randomly and symmetrically distributed. (See <a class="local">'Radiologic findings'</a> above.)</p><p>The extent of imaging studies required in each patient should be determined on a case-by-case basis. Although a whole-body radiographic bone survey would be most informative, many authors recommend a conservative "high-yield" approach to decrease exposure to radiation, which includes plain anteroposterior radiographs of the hands, wrists, feet, ankles, knees, and pelvis [<a href="#rid30">30,59</a>]. Given the benign nature of BOS, even more limited radiographic examinations can be performed in young children [<a href="#rid62">62</a>].</p><p>If performed, computed tomography (CT) shows numerous areas of hyperdense, well-rounded, sclerotic foci [<a href="#rid5">5,63</a>]. Bone scintigraphy is not usually done unless there is a suspicion for intercurrent bone metastases. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H2108611748"><span class="h3">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing is not necessary for the diagnosis of BOS in patients with characteristic clinical and radiologic findings. However, if the diagnosis is uncertain, genetic analysis for germline variants in the <em>LEMD3</em> gene may be helpful to confirm the diagnosis and differentiate BOS from other conditions associated with either CTN or sclerotic bone lesions. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H4173501717"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H1927993110"><span class="h2">Connective tissue nevi</span><span class="headingEndMark"> — </span>Connective tissue nevi (CTN) and, in particular, collagenomas can be sporadic or associated with a number of inherited or congenital disorders other than BOS, including [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eruptive collagenoma/papular elastorrhexis</strong> – Eruptive collagenoma is a rare, sporadic condition of unknown etiology characterized by acquired, numerous, discrete, firm, skin-colored papules and nodules on the trunk and upper extremities [<a href="#rid64">64,65</a>]. Eruptive collagenoma usually arises in children and young adults. On histology, lesions show thickened collagen bundles in the dermis along with decreased or degenerated elastic fibers. Indeed, "eruptive papular collageno-elastopathy" has been proposed as a new term to unify the two indistinguishable entities: eruptive collagenoma and papular elastorrhexis [<a href="#rid66">66</a>]. Fine, dense collagen is also characteristic in both, as well as in nevus anelasticus [<a href="#rid67">67</a>]. The absence of osteopoikilosis (OPK) on plain radiographs of the hands and pelvic bones and lack of an <em>LEMD3</em> mutation help to differentiate eruptive collagenoma from BOS [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial cutaneous collagenoma</strong> – Familial cutaneous collagenoma is a rare, autosomal dominant disorder characterized by the development during adolescence of multiple asymptomatic cutaneous nodules on the trunk and upper arms with histologic features of CTN [<a href="#rid68">68,69</a>]. There are no associated bone abnormalities. A splice-site mutation in the <em>LEMD</em>3 gene has been demonstrated in one kindred with familial cutaneous collagenoma [<a href="#rid70">70</a>]. This finding suggests that familial cutaneous collagenoma and BOS may be allelic disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberous sclerosis complex</strong> – Tuberous sclerosis complex is an inherited, neurocutaneous disorder characterized by pleomorphic features involving many organ systems, including multiple benign hamartomas of the brain, eyes, heart, lung, liver, kidney, and skin. Among the characteristic skin lesions, collagenoma and the so-called "shagreen patches" are firm, skin-colored to yellow-pink nodules or plaques with a dimpled surface that demonstrate histopathologic features of CTN  (<a class="graphic graphic_picture graphicRef107894" href="/z/d/graphic/107894.html" rel="external">picture 6</a>). (See  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple endocrine neoplasia type 1</strong> – Multiple endocrine neoplasia type 1 is an autosomal dominant disorder characterized by a predisposition to tumors of the parathyroid glands, anterior pituitary, and pancreatic islet cells and a predisposition to nonendocrine tumors including lipomas, facial angiofibromas, collagenomas, and melanomas [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proteus syndrome</strong> – Proteus syndrome is an extremely rare disorder comprising of malformations and overgrowth of multiple tissues. When present, a cerebriform plantar collagenoma  (<a class="graphic graphic_picture graphicRef73826" href="/z/d/graphic/73826.html" rel="external">picture 7</a>) is almost pathognomonic for Proteus syndrome. (See  <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Proteus-like syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibroblastic connective tissue nevus</strong> – Fibroblastic connective tissue nevus is a benign, cutaneous, mesenchymal lesion of fibroblastic/myofibroblastic lineage [<a href="#rid72">72</a>]. This type of CTN, formerly called a cellular CTN [<a href="#rid36">36</a>], is not found in BOS. Fibroblastic connective tissue nevus usually presents as a solitary, congenital, slow-growing, large plaque or subcutaneous mass that is often erythematous. It has no malignant potential [<a href="#rid73">73,74</a>]. Biopsy shows involvement of the deep reticular dermis and extension into the subcutis by irregular bundles of bland fibroblasts that may or may not stain with CD34 or smooth muscle actin (SMA) and entrap skin appendages [<a href="#rid73">73,74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilic fasciitis</strong> – Eosinophilic fasciitis (Schulman syndrome) is characterized by inflammation and sclerosis of the fascia and the subcutaneous tissue of the limbs associated with peripheral eosinophilia. The onset is acute, with painful edema of the extremities, followed by progressive induration that symmetrically involves the extremities (particularly the lower limbs  (<a class="graphic graphic_picture graphicRef50218" href="/z/d/graphic/50218.html" rel="external">picture 8</a>)). The skin develops an irregular, "peau d'orange" appearance. A full-thickness skin biopsy deep to the fascia confirms the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/7547.html" rel="external">"Eosinophilic fasciitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Linear localized scleroderma </strong>– Linear localized scleroderma (morphea) is an inflammatory disease characterized by the development of indurated, fibrotic skin lesions that more commonly affect the limbs  (<a class="graphic graphic_picture graphicRef51218 graphicRef78212" href="/z/d/graphic/51218.html" rel="external">picture 9A-B</a>). A skin biopsy of an early, inflammatory lesion shows an intense, inflammatory infiltrate with lymphocytes, plasma cells, macrophages, eosinophils, and mast cells. As sclerosis progresses, lesions demonstrate homogenization of the papillary dermis and thickened collagen bundles extending into the reticular dermis. (See  <a class="medical medical_review" href="/z/d/html/6399.html" rel="external">"Juvenile localized scleroderma"</a> and  <a class="medical medical_review" href="/z/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3981548649"><span class="h2">Osteopoikilosis</span><span class="headingEndMark"> — </span>The differential diagnosis of osteopoikilosis (OPK) includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoblastic bone metastases</strong> – Osteoblastic bone metastases are the most important differential diagnosis of OPK (see  <a class="medical medical_review" href="/z/d/html/91912.html" rel="external">"Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults"</a>). Cancers associated with predominantly osteoblastic bone metastasis include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prostate cancer</p><p class="bulletIndent2"><span class="glyph">•</span>Small cell lung cancer</p><p class="bulletIndent2"><span class="glyph">•</span>Breast cancer</p><p class="bulletIndent2"><span class="glyph">•</span>Carcinoid</p><p class="bulletIndent2"><span class="glyph">•</span>Hodgkin lymphoma</p><p class="bulletIndent2"><span class="glyph">•</span>Medulloblastoma</p><p></p><p class="bulletIndent1">Osteoblastic metastatic lesions are commonly located in the axial skeleton and proximal femur, are more asymmetric than OPK, and are often associated with pain. Skeletal scintigraphy with technetium-99m is the initial and most widely used method to detect osteoblastic bone metastases, which characteristically produce "hot spots" on bone scans due to increased radioisotope uptake [<a href="#rid23">23,63,75</a>]. (See  <a class="medical medical_review" href="/z/d/html/91912.html" rel="external">"Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults", section on 'Detection and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign focal osteosclerotic lesions</strong> – Osteoid osteoma is a benign, bone-forming tumor, most commonly located in the long bones (eg, femur, tibia) and spine. It presents during the second decade of life in most cases and is typically associated with pain. Radiographs show a small, round lucency (nidus) with a sclerotic margin. (See  <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">"Nonmalignant bone lesions in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1">Enostosis (bone island) is a compact focus of cortical bone within the spongiosa or cancellous bone. Enostosis presents as oval, &lt;1 cm, unilateral lesions that mainly involve the axial skeleton or long bones [<a href="#rid76">76</a>]. Enostosis is asymptomatic and typically an incidental finding on radiographs.</p><p></p><p class="bulletIndent1">Focal osteosclerotic lesions may also occur in adults with systemic mastocytosis, but in contrast with OPK, they are predominantly located in the axial skeleton [<a href="#rid77">77,78</a>]. (See  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Sclerotic bone lesions are a common finding associated with tuberous sclerosis complex [<a href="#rid79">79,80</a>], varying in size from 0.2 mm to 3 cm in the cranial bones, vertebrae, ribs, and pelvis. (See  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> <strong>hereditary sclerosing bone dysplasias</strong> – OPK may be confused with other rare, hereditary sclerosing bone dysplasias, including osteopetrosis,<strong> </strong>pyknodysostosis, osteopathia striata, and multiple diaphyseal sclerosis (ribbing disease) [<a href="#rid26">26,81,82</a>]. (See  <a class="medical medical_review" href="/z/d/html/108252.html" rel="external">"Skeletal dysplasias: Specific disorders", section on 'High bone density'</a> and  <a class="medical medical_review" href="/z/d/html/13551.html" rel="external">"Skeletal dysplasias: Approach to evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Skeletal fluorosis and renal osteodystrophy may also present with areas of osteocondensation that favor the axial skeleton [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p></p><p class="headingAnchor" id="H3863524539"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>BOS is a benign disorder that does not require treatment. A<strong> </strong>correct diagnosis is therefore essential to spare patients from unnecessary investigations and interventions [<a href="#rid32">32</a>]. However, some patients may desire surgical excision of connective tissue nevi (CTN) because of cosmetic concerns.</p><p>Analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) may be indicated for pain relief in patients with osteopoikilosis (OPK) who are symptomatic [<a href="#rid23">23</a>]. There are anecdotal reports of benefit with systemic bisphosphonates for patients with melorheostosis associated with severe pain and limitation of function [<a href="#rid84">84-86</a>].</p><p class="headingAnchor" id="H150719894"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>BOS is a benign condition and generally carries an excellent prognosis. Patients, parents, and/or caregivers should be reassured that they can live an active life and expect a normal lifespan.</p><p>There is no specific follow-up required for most patients with BOS, especially if they are asymptomatic. Baseline documentation of skin and bone lesions when discovered is important in order to prevent any misdiagnoses in the future.</p><p class="headingAnchor" id="H1607933396"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis</strong> – Buschke-Ollendorff syndrome (BOS) is a rare, inherited, autosomal dominant disorder with high penetrance and variable expressivity caused by loss-of-function germline mutations in the LEM domain-containing protein 3 (<em>LEMD3</em>) gene and characterized by the presence of sclerotic bone lesions (osteopoikilosis [OPK]) and, less commonly, melorheostosis in association with connective tissue nevi (CTN). (See <a class="local">'Introduction'</a> above and <a class="local">'Genetics and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – CTN present as disseminated, flesh-colored or yellowish papules or as more localized, grouped nodules or plaques  (<a class="graphic graphic_picture graphicRef107838" href="/z/d/graphic/107838.html" rel="external">picture 3B</a>). OPK is a sclerosing bone dysplasia that typically affects the small tubular bones of the hands and feet, epiphyseal region of the long bones, and the pelvic bones. OPK is usually asymptomatic and an incidental finding on imaging studies for unrelated conditions, but some patients may report articular pain. Melorheostosis is a rare, sclerosing dysplasia of the bone with a radiologic appearance of "dripping candle wax." It is typically unilateral with a predilection for the lower limbs and is asymptomatic in most cases. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of BOS is based upon the finding of multiple cutaneous lesions with histopathologic features of CTN associated with OPK detected on plain radiographs. Genetic analysis for germline mutations in the <em>LEMD3</em> gene can confirm the diagnosis in uncertain cases. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – BOS is a benign disorder that does not require treatment. Surgical excision of CTN may rarely be performed in some patients for cosmetic reasons. Analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) may be indicated in patients with OPK who are symptomatic. (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Online Mendelian Inheritance in Man: Buschke-Ollendorff syndrome. www.omim.org/entry/166700 (Accessed on January 10, 2023).</li><li><a class="nounderline abstract_t">Pope V, Dupuis L, Kannu P, et al. Buschke-Ollendorff syndrome: a novel case series and systematic review. Br J Dermatol 2016; 174:723.</a></li><li><a class="nounderline abstract_t">Salik D, Dupire G, Sass U, et al. Variable expressivity in Buschke-Ollendorff syndrome. Ann Dermatol Venereol 2022; 149:128.</a></li><li><a class="nounderline abstract_t">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.</a></li><li><a class="nounderline abstract_t">Korkmaz MF, Elli M, Özkan MB, et al. Osteopoikilosis: report of a familial case and review of the literature. Rheumatol Int 2015; 35:921.</a></li><li><a class="nounderline abstract_t">Borman P, Ozoran K, Aydoğ S, Coşkun S. Osteopoikilosis: report of a clinical case and review of the literature. Joint Bone Spine 2002; 69:230.</a></li><li><a class="nounderline abstract_t">Yadegari M, Whyte MP, Mumm S, et al. Buschke-Ollendorff syndrome: absence of LEMD3 mutation in an affected family. Arch Dermatol 2010; 146:63.</a></li><li><a class="nounderline abstract_t">Hellemans J, Preobrazhenska O, Willaert A, et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet 2004; 36:1213.</a></li><li><a class="nounderline abstract_t">Kratzsch J, Mitter D, Ziemer M, et al. Identification of a Novel Point Mutation in the LEMD3 Gene in an Infant With Buschke-Ollendorff Syndrome. JAMA Dermatol 2016; 152:844.</a></li><li><a class="nounderline abstract_t">Zhang Y, Castori M, Ferranti G, et al. Novel and recurrent germline LEMD3 mutations causing Buschke-Ollendorff syndrome and osteopoikilosis but not isolated melorheostosis. Clin Genet 2009; 75:556.</a></li><li><a class="nounderline abstract_t">Takashima S, Fujita Y, Suzuki S, et al. RNA recognition motif of LEMD3 as a key player in the pathogenesis of Buschke-Ollendorff syndrome. J Dermatol Sci 2016; 81:205.</a></li><li><a class="nounderline abstract_t">Condorelli A, Musso N, Scuderi L, et al. Juvenile elastoma without germline mutations in LEMD3 gene: A case of Buschke-Ollendorff syndrome? Pediatr Dermatol 2017; 34:e345.</a></li><li><a class="nounderline abstract_t">Korman B, Wei J, Laumann A, et al. Mutation in LEMD3 (Man1) Associated with Osteopoikilosis and Late-Onset Generalized Morphea: A New Buschke-Ollendorf Syndrome Variant. Case Rep Dermatol Med 2016; 2016:2483041.</a></li><li><a class="nounderline abstract_t">Lafargue O, Fraitag S, Boccara O, et al. [Extensive connective tissue nevus in children]. Ann Dermatol Venereol 2017; 144:700.</a></li><li><a class="nounderline abstract_t">Jain A, Selvam P, Atwal H, Atwal PS. A Report of a Novel Pathogenic Variant in a Family with Buschke-Ollendorf Syndrome. J Pediatr Genet 2020; 9:63.</a></li><li><a class="nounderline abstract_t">Yoo IY, Song JS, Ki CS, et al. Novel 4-bp Intronic Deletion (c.1560+5_1560+8del) [corrected] in LEMD3 in a Korean Patient With Osteopoikilosis. Ann Lab Med 2017; 37:540.</a></li><li><a class="nounderline abstract_t">Yuste-Chaves M, Cañueto J, Santos-Briz Á, et al. Buschke-Ollendorff syndrome with striking phenotypic variation resulting from a novel c.2203C&gt;T nonsense mutation in LEMD3. Pediatr Dermatol 2011; 28:447.</a></li><li><a class="nounderline abstract_t">Xu Z, Yang C, Xue R. Buschke-Ollendorff syndrome with LEMD3 germline stopgain mutation p.R678* presenting as multiple subcutaneous nodules with mucin deposition. J Cutan Pathol 2021; 48:77.</a></li><li><a class="nounderline abstract_t">Elmaoğulları S, Yıldız AE, Demir S, et al. A novel LEMD3 pathogenic variant in a son and mother with osteopoikilosis. Turk J Pediatr 2019; 61:594.</a></li><li><a class="nounderline abstract_t">Miyazono KI, Ohno Y, Wada H, et al. Structural basis for receptor-regulated SMAD recognition by MAN1. Nucleic Acids Res 2018; 46:12139.</a></li><li><a class="nounderline abstract_t">Giro MG, Duvic M, Smith LT, et al. Buschke-Ollendorff syndrome associated with elevated elastin production by affected skin fibroblasts in culture. J Invest Dermatol 1992; 99:129.</a></li><li><a class="nounderline abstract_t">Uitto J, Santa Cruz DJ, Starcher BC, et al. Biochemical and ultrastructural demonstration of elastin accumulation in the skin lesions of the Buschke-Ollendorff syndrome. J Invest Dermatol 1981; 76:284.</a></li><li><a class="nounderline abstract_t">Woyciechowsky TG, Monticielo MR, Keiserman B, Monticielo OA. Osteopoikilosis: what does the rheumatologist must know about it? Clin Rheumatol 2012; 31:745.</a></li><li><a class="nounderline abstract_t">Wordsworth P, Chan M. Melorheostosis and Osteopoikilosis: A Review of Clinical Features and Pathogenesis. Calcif Tissue Int 2019; 104:530.</a></li><li><a class="nounderline abstract_t">Debeer P, Pykels E, Lammens J, et al. Melorheostosis in a family with autosomal dominant osteopoikilosis: report of a third family. Am J Med Genet A 2003; 119A:188.</a></li><li><a class="nounderline abstract_t">Boulet C, Madani H, Lenchik L, et al. Sclerosing bone dysplasias: genetic, clinical and radiology update of hereditary and non-hereditary disorders. Br J Radiol 2016; 89:20150349.</a></li><li><a class="nounderline abstract_t">Baasanjav S, Jamsheer A, Kolanczyk M, et al. Osteopoikilosis and multiple exostoses caused by novel mutations in LEMD3 and EXT1 genes respectively--coincidence within one family. BMC Med Genet 2010; 11:110.</a></li><li><a class="nounderline abstract_t">Gutierrez D, Cooper KD, Mitchell AL, Cohn HI. Novel Somatic Mutation in LEMD3 Splice Site Results in Buschke-Ollendorff Syndrome with Polyostotic Melorheostosis and Osteopoikilosis. Pediatr Dermatol 2015; 32:e219.</a></li><li><a class="nounderline abstract_t">Kang H, Jha S, Deng Z, et al. Somatic activating mutations in MAP2K1 cause melorheostosis. Nat Commun 2018; 9:1390.</a></li><li><a class="nounderline abstract_t">McCuaig CC, Vera C, Kokta V, et al. Connective tissue nevi in children: institutional experience and review. J Am Acad Dermatol 2012; 67:890.</a></li><li><a class="nounderline abstract_t">Socrier Y, Wann AR, Sigal ML, et al. [Buschke-Ollendorff syndrome]. Ann Dermatol Venereol 2014; 141:164.</a></li><li><a class="nounderline abstract_t">Surrenti T, Callea F, De Horatio LT, et al. Buschke-Ollendorff syndrome: sparing unnecessary investigations. Cutis 2014; 94:97.</a></li><li><a class="nounderline abstract_t">Cañueto J, Román C, Santos-Briz Á, et al. Papular elastorrhexis and Buschke-Ollendorff syndrome are different entities. J Am Acad Dermatol 2011; 65:e7.</a></li><li><a class="nounderline abstract_t">Danielsen L, Midtgaard K, Christensen HE. Osteopoikilosis associated with dermatofibrosis lenticularis disseminata. Arch Dermatol 1969; 100:465.</a></li><li><a class="nounderline abstract_t">Foo CC, Kumarasinghe SP. Juvenile elastoma: a forme fruste of the Buschke-Ollendorff syndrome? Australas J Dermatol 2005; 46:250.</a></li><li><a class="nounderline abstract_t">Saussine A, Marrou K, Delanoé P, et al. Connective tissue nevi: an entity revisited. J Am Acad Dermatol 2012; 67:233.</a></li><li><a class="nounderline abstract_t">Lee MY, Byun JY, Choi HY, Choi YW. Mucinous Nevus. Ann Dermatol 2018; 30:465.</a></li><li><a class="nounderline abstract_t">Hellemans J, Debeer P, Wright M, et al. Germline LEMD3 mutations are rare in sporadic patients with isolated melorheostosis. Hum Mutat 2006; 27:290.</a></li><li><a class="nounderline abstract_t">Benli IT, Akalin S, Boysan E, et al. Epidemiological, clinical and radiological aspects of osteopoikilosis. J Bone Joint Surg Br 1992; 74:504.</a></li><li><a class="nounderline abstract_t">Chigira M, Kato K, Mashio K, Shinozaki T. Symmetry of bone lesions in osteopoikilosis. Report of 4 cases. Acta Orthop Scand 1991; 62:495.</a></li><li><a class="nounderline abstract_t">Hasan SA, Siddiq AB, Moula A, et al. Osteopoikilosis. Mymensingh Med J 2010; 19:290.</a></li><li><a class="nounderline abstract_t">Quezada-Chavarría G, Quezada-Cuevas SE, Ramírez-Serrallonga R. [Osteopoikilosis. A case report]. Gac Med Mex 2004; 140:633.</a></li><li><a class="nounderline abstract_t">Negi RS, Manchanda KL, Sanga S, et al. Osteopoikilosis - Spotted bone disease. Med J Armed Forces India 2013; 69:196.</a></li><li><a class="nounderline abstract_t">Jha S, Cowen EW, Lehky TJ, et al. Clinical Evaluation of Melorheostosis in the Context of a Natural History Clinical Study. JBMR Plus 2019; 3:e10214.</a></li><li><a class="nounderline abstract_t">Gnoli M, Staals EL, Campanacci L, et al. Melorheostosis and Osteopoikilosis Clinical and Molecular Description of an Italian Case Series. Calcif Tissue Int 2019; 105:215.</a></li><li><a class="nounderline abstract_t">Giardullo L, Altomare A, Rotondo C, et al. Osteoblast Dysfunction in Non-Hereditary Sclerosing Bone Diseases. Int J Mol Sci 2021; 22.</a></li><li><a class="nounderline abstract_t">Smith GC, Pingree MJ, Freeman LA, et al. Melorheostosis: A Retrospective Clinical Analysis of 24 Patients at the Mayo Clinic. PM R 2017; 9:283.</a></li><li><a class="nounderline abstract_t">Jha S, Ivovic A, Kang H, et al. Distribution and Functional Consequences of Somatic MAP2K1 Variants in Affected Skin Associated with Bone Lesions in Melorheostosis. J Invest Dermatol 2021; 141:688.</a></li><li><a class="nounderline abstract_t">Greenspan A, Azouz EM. Bone dysplasia series. Melorheostosis: review and update. Can Assoc Radiol J 1999; 50:324.</a></li><li><a class="nounderline abstract_t">Hung WK, Shen MH, Chen KY, et al. Buschke-Ollendorff syndrome presenting with asymptomatic yellowish papules and leg length discrepancy: A case report. J Musculoskelet Neuronal Interact 2022; 22:292.</a></li><li><a class="nounderline abstract_t">Salaria AK, Singh G, Dogra E, et al. A Highly Unusual Clinical Presentation and Imaging Appearance of a Rare Diseases: Melorheostosis. J Orthop Case Rep 2020; 10:72.</a></li><li><a class="nounderline abstract_t">Di Altobrando A, Neri I, Gurioli C, et al. Case of melorheostosis associated with ipsilateral verrucous epidermal nevus, linear connective tissue nevus, diffuse hyperpigmentation and hypertrichosis: A fortuitous coincidence? J Dermatol 2020; 47:1063.</a></li><li><a class="nounderline abstract_t">Jha S, Fratzl-Zelman N, Roschger P, et al. Distinct Clinical and Pathological Features of Melorheostosis Associated With Somatic MAP2K1 Mutations. J Bone Miner Res 2019; 34:145.</a></li><li><a class="nounderline abstract_t">Han X, Xu Y, Wei Z, et al. Clinical characteristics of 10 Chinese patients with melorheostosis and identification of a somatic MAP2K1 variant in one case. Mol Genet Genomic Med 2022; 10:e2043.</a></li><li><a class="nounderline abstract_t">Tinschert S, Stein A, Göldner B, et al. Melorheostosis with ipsilateral nevus sebaceus (didymosis melorheosebacea). Eur J Dermatol 2003; 13:21.</a></li><li><a class="nounderline abstract_t">Buysse K, Reardon W, Mehta L, et al. The 12q14 microdeletion syndrome: additional patients and further evidence that HMGA2 is an important genetic determinant for human height. Eur J Med Genet 2009; 52:101.</a></li><li><a class="nounderline abstract_t">Dawson AL, Schulman JM, Jordan RC, North JP. Ossifying fibroma in Buschke-Ollendorff syndrome. J Cutan Pathol 2014; 41:740.</a></li><li><a class="nounderline abstract_t">Fernández-Faith E, Kress D, Piliang M, et al. Buschke-Ollendorff syndrome and bilateral cutaneous syndactyly. Pediatr Dermatol 2012; 29:661.</a></li><li><a class="nounderline abstract_t">Schnur RE, Grace K, Herzberg A. Buschke-Ollendorff syndrome, otosclerosis, and congenital spinal stenosis. Pediatr Dermatol 1994; 11:31.</a></li><li><a class="nounderline abstract_t">Korekawa A, Nakano H, Toyomaki Y, et al. Buschke-Ollendorff syndrome associated with hypertrophic scar formation: a possible role for LEMD3 mutation. Br J Dermatol 2012; 166:900.</a></li><li><a class="nounderline abstract_t">Gracia-Cazaña T, Frias M, Roselló R, et al. PASH syndrome associated with osteopoikilosis. Int J Dermatol 2015; 54:e369.</a></li><li><a class="nounderline abstract_t">Verbov J. Buschke--Ollendorff syndrome (disseminated dermatofibrosis with osteopoikilosis). Br J Dermatol 1977; 96:87.</a></li><li><a class="nounderline abstract_t">Tuncel M, Caner B. Osteopoikilosis: a major diagnostic problem solved by bone scintigraphy. Rev Esp Med Nucl Imagen Mol 2012; 31:93.</a></li><li><a class="nounderline abstract_t">Sharma R, Verma P, Singal A, Sharma S. Eruptive collagenoma. Indian J Dermatol Venereol Leprol 2013; 79:256.</a></li><li><a class="nounderline abstract_t">McClung AA, Blumberg MA, Huttenbach Y, et al. Development of collagenomas during pregnancy. J Am Acad Dermatol 2005; 53:S150.</a></li><li><a class="nounderline abstract_t">Kuwatsuka S, Kuwatsuka Y, Tomimura S, Utani A. Proposal of the new name "eruptive papular collageno-elastopathy" to unify the two indistinguishable entities, eruptive collagenoma and papular elastorrhexis. J Dermatol 2015; 42:440.</a></li><li><a class="nounderline abstract_t">Lee SH, Sung NH. The Importance of Collagen Tissue in Papular Elastorrhexis, Eruptive Collagenoma, and Nevus Anelasticus. Ann Dermatol 2016; 28:210.</a></li><li><a class="nounderline abstract_t">Uitto J, Santa-Cruz DJ, Eisen AZ. Familial cutaneous collagenoma: genetic studies on a family. Br J Dermatol 1979; 101:185.</a></li><li><a class="nounderline abstract_t">Park MY, Choi YJ, Lee JY, et al. A case of familial cutaneous collagenoma. Ann Dermatol 2011; 23 Suppl 1:S119.</a></li><li><a class="nounderline abstract_t">Hershkovitz D, Amitai B, Sprecher E. Familial cutaneous collagenomas resulting from a novel mutation in LEMD3. Br J Dermatol 2007; 156:375.</a></li><li><a class="nounderline abstract_t">Vidal A, Iglesias MJ, Fernández B, et al. Cutaneous lesions associated to multiple endocrine neoplasia syndrome type 1. J Eur Acad Dermatol Venereol 2008; 22:835.</a></li><li><a class="nounderline abstract_t">de Feraudy S, Fletcher CD. Fibroblastic connective tissue nevus: a rare cutaneous lesion analyzed in a series of 25 cases. Am J Surg Pathol 2012; 36:1509.</a></li><li><a class="nounderline abstract_t">Bouaoud J, Fraitag S, Soupre V, et al. Congenital fibroblastic connective tissue nevi: Unusual and misleading presentations in three infantile cases. Pediatr Dermatol 2018; 35:644.</a></li><li><a class="nounderline abstract_t">Pennacchia I, Kutzner H, Kazakov DV, Mentzel T. Fibroblastic connective tissue nevus: Clinicopathological and immunohistochemical study of 14 cases. J Cutan Pathol 2017; 44:827.</a></li><li><a class="nounderline abstract_t">Ozdemirel AE, Cakit BD, Erdem HR, Koc B. A rare benign disorder mimicking metastasis on radiographic examination: a case report of osteopoikilosis. Rheumatol Int 2011; 31:1113.</a></li><li><a class="nounderline abstract_t">Shah J, Gandhi D, Chauhan A, Gupta S. Imaging Review of Pediatric Benign Osteocytic Tumors and Latest Updates on Management. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Rossini M, Zanotti R, Viapiana O, et al. Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin North Am 2014; 34:383.</a></li><li><a class="nounderline abstract_t">Alpay Kanıtez N, Erer B, Doğan Ö, et al. Osteoporosis and osteopathy markers in patients with mastocytosis. Turk J Haematol 2015; 32:43.</a></li><li><a class="nounderline abstract_t">Boronat S, Barber I, Thiele EA. Sclerotic bone lesions in tuberous sclerosis complex: A genotype-phenotype study. Am J Med Genet A 2017; 173:1891.</a></li><li><a class="nounderline abstract_t">Brakemeier S, Vogt L, Adams LC, et al. Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex. Sci Rep 2018; 8:953.</a></li><li><a class="nounderline abstract_t">Boudin E, Van Hul W. Sclerosing bone dysplasias. Best Pract Res Clin Endocrinol Metab 2018; 32:707.</a></li><li><a class="nounderline abstract_t">Ihde LL, Forrester DM, Gottsegen CJ, et al. Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics 2011; 31:1865.</a></li><li><a class="nounderline abstract_t">Sellami M, Riahi H, Maatallah K, et al. Skeletal fluorosis: don't miss the diagnosis! Skeletal Radiol 2020; 49:345.</a></li><li><a class="nounderline abstract_t">Slimani S, Nezzar A, Makhloufi H. Successful treatment of pain in melorheostosis with zoledronate, with improvement on bone scintigraphy. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Sathish M, Girinivasan C, Srinivasacholan C, Gowtham P. Bisphosphonate Therapy in the Management of Symptomatic Melorheostosis of Tibia. J Orthop Case Rep 2021; 11:103.</a></li><li><a class="nounderline abstract_t">Lokesh M, Muthumanickam, Kumar SS, Gadde S. Dripping Wax Bone Disease - Melorheostosis - A Rare Case Scenario. J Orthop Case Rep 2020; 10:94.</a></li></ol></div><div id="topicVersionRevision">Topic 15515 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.omim.org/entry/166700" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Online Mendelian Inheritance in Man: Buschke-Ollendorff syndrome. www.omim.org/entry/166700 (Accessed on January 10, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26708699" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Buschke-Ollendorff syndrome: a novel case series and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34511237" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Variable expressivity in Buschke-Ollendorff syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25352085" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Osteopoikilosis: report of a familial case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12027319" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Osteopoikilosis: report of a clinical case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083694" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Buschke-Ollendorff syndrome: absence of LEMD3 mutation in an affected family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489854" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27007781" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identification of a Novel Point Mutation in the LEMD3 Gene in an Infant With Buschke-Ollendorff Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438932" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Novel and recurrent germline LEMD3 mutations causing Buschke-Ollendorff syndrome and osteopoikilosis but not isolated melorheostosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26711937" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : RNA recognition motif of LEMD3 as a key player in the pathogenesis of Buschke-Ollendorff syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29023873" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Juvenile elastoma without germline mutations in LEMD3 gene: A case of Buschke-Ollendorff syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27382493" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mutation in LEMD3 (Man1) Associated with Osteopoikilosis and Late-Onset Generalized Morphea: A New Buschke-Ollendorf Syndrome Variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28760502" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : [Extensive connective tissue nevus in children].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31976147" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A Report of a Novel Pathogenic Variant in a Family with Buschke-Ollendorf Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28840995" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Novel 4-bp Intronic Deletion (c.1560+5_1560+8del) [corrected] in LEMD3 in a Korean Patient With Osteopoikilosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20678097" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Buschke-Ollendorff syndrome with striking phenotypic variation resulting from a novel c.2203C&gt;T nonsense mutation in LEMD3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32519343" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Buschke-Ollendorff syndrome with LEMD3 germline stopgain mutation p.R678* presenting as multiple subcutaneous nodules with mucin deposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990479" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A novel LEMD3 pathogenic variant in a son and mother with osteopoikilosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30321401" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Structural basis for receptor-regulated SMAD recognition by MAN1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1629625" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Buschke-Ollendorff syndrome associated with elevated elastin production by affected skin fibroblasts in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7205030" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Biochemical and ultrastructural demonstration of elastin accumulation in the skin lesions of the Buschke-Ollendorff syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22246417" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Osteopoikilosis: what does the rheumatologist must know about it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30989250" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Melorheostosis and Osteopoikilosis: A Review of Clinical Features and Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12749062" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Melorheostosis in a family with autosomal dominant osteopoikilosis: report of a third family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26898950" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sclerosing bone dysplasias: genetic, clinical and radiology update of hereditary and non-hereditary disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20618940" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Osteopoikilosis and multiple exostoses caused by novel mutations in LEMD3 and EXT1 genes respectively--coincidence within one family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135202" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Novel Somatic Mutation in LEMD3 Splice Site Results in Buschke-Ollendorff Syndrome with Polyostotic Melorheostosis and Osteopoikilosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29643386" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Somatic activating mutations in MAP2K1 cause melorheostosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22739355" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Connective tissue nevi in children: institutional experience and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24507217" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : [Buschke-Ollendorff syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25184645" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Buschke-Ollendorff syndrome: sparing unnecessary investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679808" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Papular elastorrhexis and Buschke-Ollendorff syndrome are different entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5358111" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Osteopoikilosis associated with dermatofibrosis lenticularis disseminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16197425" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Juvenile elastoma: a forme fruste of the Buschke-Ollendorff syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22014540" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Connective tissue nevi: an entity revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30065589" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mucinous Nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470551" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Germline LEMD3 mutations are rare in sporadic patients with isolated melorheostosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1624505" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Epidemiological, clinical and radiological aspects of osteopoikilosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1950500" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Symmetry of bone lesions in osteopoikilosis. Report of 4 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395928" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Osteopoikilosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15633571" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : [Osteopoikilosis. A case report].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24600101" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Osteopoikilosis - Spotted bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31485554" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical Evaluation of Melorheostosis in the Context of a Natural History Clinical Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31129707" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Melorheostosis and Osteopoikilosis Clinical and Molecular Description of an Italian Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34360745" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Osteoblast Dysfunction in Non-Hereditary Sclerosing Bone Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27485676" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Melorheostosis: A Retrospective Clinical Analysis of 24 Patients at the Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32791068" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Distribution and Functional Consequences of Somatic MAP2K1 Variants in Affected Skin Associated with Bone Lesions in Melorheostosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555508" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Bone dysplasia series. Melorheostosis: review and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35642708" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Buschke-Ollendorff syndrome presenting with asymptomatic yellowish papules and leg length discrepancy: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33489974" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A Highly Unusual Clinical Presentation and Imaging Appearance of a Rare Diseases: Melorheostosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32656852" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Case of melorheostosis associated with ipsilateral verrucous epidermal nevus, linear connective tissue nevus, diffuse hyperpigmentation and hypertrichosis: A fortuitous coincidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30138550" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Distinct Clinical and Pathological Features of Melorheostosis Associated With Somatic MAP2K1 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36004822" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical characteristics of 10 Chinese patients with melorheostosis and identification of a somatic MAP2K1 variant in one case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12609776" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Melorheostosis with ipsilateral nevus sebaceus (didymosis melorheosebacea).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19298872" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The 12q14 microdeletion syndrome: additional patients and further evidence that HMGA2 is an important genetic determinant for human height.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24917176" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ossifying fibroma in Buschke-Ollendorff syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22150319" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Buschke-Ollendorff syndrome and bilateral cutaneous syndactyly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170846" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Buschke-Ollendorff syndrome, otosclerosis, and congenital spinal stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21985280" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Buschke-Ollendorff syndrome associated with hypertrophic scar formation: a possible role for LEMD3 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26175185" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : PASH syndrome associated with osteopoikilosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/843441" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Buschke--Ollendorff syndrome (disseminated dermatofibrosis with osteopoikilosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658816" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Osteopoikilosis: a major diagnostic problem solved by bone scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23442476" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Eruptive collagenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021167" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Development of collagenomas during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25703267" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Proposal of the new name "eruptive papular collageno-elastopathy" to unify the two indistinguishable entities, eruptive collagenoma and papular elastorrhexis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27081269" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The Importance of Collagen Tissue in Papular Elastorrhexis, Eruptive Collagenoma, and Nevus Anelasticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/486326" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Familial cutaneous collagenoma: genetic studies on a family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22028557" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A case of familial cutaneous collagenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223882" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Familial cutaneous collagenomas resulting from a novel mutation in LEMD3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18435740" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cutaneous lesions associated to multiple endocrine neoplasia syndrome type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22892597" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Fibroblastic connective tissue nevus: a rare cutaneous lesion analyzed in a series of 25 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30024070" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Congenital fibroblastic connective tissue nevi: Unusual and misleading presentations in three infantile cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28632950" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Fibroblastic connective tissue nevus: Clinicopathological and immunohistochemical study of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21120491" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A rare benign disorder mimicking metastasis on radiographic examination: a case report of osteopoikilosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34206870" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Imaging Review of Pediatric Benign Osteocytic Tumors and Latest Updates on Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24745681" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bone involvement and osteoporosis in mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25805674" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Osteoporosis and osteopathy markers in patients with mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28488386" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Sclerotic bone lesions in tuberous sclerosis complex: A genotype-phenotype study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29343816" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30449550" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sclerosing bone dysplasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22084176" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31501957" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Skeletal fluorosis: don't miss the diagnosis!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813581" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Successful treatment of pain in melorheostosis with zoledronate, with improvement on bone scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35415166" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Bisphosphonate Therapy in the Management of Symptomatic Melorheostosis of Tibia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34169026" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Dripping Wax Bone Disease - Melorheostosis - A Rare Case Scenario.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
